Review Article

Diagnostic Imaging Modalities for Skeletal Metastasis in Soft Tissue Sarcoma

Negar Khosravi, Masoud Mirkazemi, Sadegh Saberi, Seyed Ali Ebrahimi , Mehraneh Saghi, Azra Izanloo

Negar Khosravi
Student Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran.

Masoud Mirkazemi
Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, IR Iran.

Sadegh Saberi
Joint Reconstruction Research Center (JRRC), Orthopedic Department of Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Seyed Ali Ebrahimi
Student Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran.. Email: seyedaliebrahimy@gmail.com

Mehraneh Saghi
Student Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran.

Azra Izanloo
Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad,Iran
Online First: February 02, 2020 | Cite this Article
Khosravi, N., Mirkazemi, M., Saberi, S., Ebrahimi, S., Saghi, M., Izanloo, A. 2020. Diagnostic Imaging Modalities for Skeletal Metastasis in Soft Tissue Sarcoma. The Cancer Press 6(1): 1-7. DOI:10.15562/tcp.82


Soft tissue sarcomas (STS) are usually highly malignant. Bone metastasis is less common in STS but it significantly affects patients` quality of life and also is indicator of poor prognosis. Different types of imaging modalities are available for diagnosis and follow-up of STS. Bone scintigraphy is a sensitive and cost effective method for screening bone metastases however it`s poor specificity must be covered by other imaging methods like computed tomography. More sophisticated methods are available including whole body magnetic resonance imaging (MRI) and positron emission tomography (PET). Equipment limitations and high costs are the main problems with ofthese methods.

References

Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. The lancet oncology. 2012;13(10):1045-54.

Putnam JJ, Roth JA, Wesley M, Johnston M, Rosenberg S. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. The Journal of thoracic and cardiovascular surgery. 1984;87(2):260-8.

Yoshikawa H, Ueda T, Mori S, Araki N, Kuratsu S, Uchida A, Ochi T. Skeletal metastases from soft-tissue sarcomas. Incidence, patterns, and radiological features. The Journal of bone and jointsurgery British volume. 1997;79(4):548-52.

Yoshikawa H, Myoui A, Ochi T, Araki N, Ueda T, Kudawara I, Nakanishi K, Tanaka H, Nakamura H. Bone Metastases from Soft Tissue Sarcomas. Seminars in musculoskeletal radiology. 1999;3(2):183-90.

Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nature reviews Clinical oncology. 2014;11(6):335-45.

Łukaszewski B, Nazar J, Goch M, Łukaszewska M, Stępiński A, Jurczyk MU. Diagnostic methods for detection ofbone metastases. Contemp Oncol (Pozn). 2017;21(2):98-103.

Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. Journal of Nuclear Medicine. 2003;44(2):184-91.

Vincenzi B, Frezza AM, Schiavon G, Santini D, Dileo P, Silletta M, Delisi D, Bertoldo F, Badalamenti G, Baldi GG, Zovato S, Berardi R, Tucci M, Silvestris F, Dei Tos AP, Tirabosco R, Whelan JS, Tonini G. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clinical sarcoma research. 2013;3(1):6.

Jager PL, Hoekstra HJ, Leeuw JA, van der Graaf WT, de Vries EG, Piers DA. Routine bone scintigraphy in primary staging of soft tissue sarcoma: Is it worthwhile? Cancer. 2000;89(8):1726-31.

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research. 2006;12(20):6243s-9s.

ChowE, Fan G, Hadi S, Filipczak L. Symptom clusters in cancer patients with bone metastases. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2007;15(9):1035-43.

Brodowicz T, Hadji P, Niepel D, Diel I. Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer. Cancer treatment reviews. 2017;61:23-34.

Söderlund V. Radiological diagnosisof skeletal metastases. European radiology. 1996;6(5):587-95.

Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev. 1996;22(4):289-331.

Coleman R. Monitoring of bone metastases. European Journal of Cancer. 1998;34(2):252-9.

Kido DK, Gould R, Taati F, Duncan A, Schnur J. Comparative sensitivity of CT scans, radiographs and radionuclide bone scans in detecting metastatic calvarial lesions. Radiology. 1978;128(2):371-5.

Sundaram M, McGuire MH. Computed tomography or magnetic resonance for evaluating the solitary tumor or tumor-like lesion of bone? Skeletal radiology. 1988;17(6):393-401.

Traill Z, Richards M, Moore N. Magnetic resonance imaging of metastatic bone disease. Clinical orthopaedics and related research. 1995(312):76-88.

Barai S, Bandopadhayaya G, Chumber S, Gupta D, Patel C, Dhanpati H. Role of skeletal scintigraphy in soft tissue sarcoma: Improving the diagnostic yield. Journal of postgraduate medicine. 2004;50(3):180.

Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jürgens H, Schober O, Rummeny EJ. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. American Journal of Roentgenology. 2001;177(1):229-36.

Merrick M, Beales J, Garvie N, Leonard R. Evaluation and skeletal metastases. The British journal of radiology. 1992;65(777):803-6.

Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, Finn RD, Ready D, Horowitz SM, Goldsmith SJ. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nuclear medicine and biology. 1996;23(6):693-7.

Krasnow AZ, HellmanRS, Timins ME, Collier BD, Anderson T, Isitman AT, editors. Diagnostic bone scanning in oncology. Seminars in nuclear medicine; 1997: Elsevier.

Dose J, Bleckmann C, Bachmann S, Bohuslavizki K, Berger J, Jenicke L, Habermann C, Jänicke F. Comparison offluorodeoxyglucose positron emission tomography and ‘conventional diagnostic procedures’ for the detection of distant metastases in breast cancer patients. Nuclear medicine communications. 2002;23(9):857-64.

Ben Arush MW, Israel O, Kedar Z, GoralnikL, Best LA, Meushar N, Elhasid R, Postovsky S. Detection of isolated distant metastasis in soft tissue sarcoma by fluorodeoxyglucose positron emission tomography: case report. Pediatric hematology and oncology. 2001;18(4):295-8.


No Supplementary Material available for this article.
Article Views      : 224
PDF Downloads : 81